Avanir Pharmaceuticals
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Avanir Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count).
Avanir Pharmaceuticals: 15 sponsored US clinical trials, none currently recruiting.
Avanir Pharmaceuticals sponsors 15 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 14 completed. 8 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depressive Disorder, Treatment-Resistant, with 1 trials.
Top-decile sponsor footprint
Avanir Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#934 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
14 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (93.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
15 total, page 1 of 1
Study to Assess the Bioavailability, Pharmacokinetics, Safety, and Tolerability of AVP-923 in Healthy Adult Participants
NCT03381664
Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia
NCT02477670
Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA)
NCT02496039
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
NCT02153502
Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
NCT01767129
Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
NCT01799941
Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease
NCT01584440
Efficacy and Safety of 20 mg Sumatriptan Powder Delivered Intranasally With the Bi-directional Device Compared With 100 mg Sumatriptan Tablets in Adults With Acute Migraine With or Without Aura
NCT01667679
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
NCT01324232
PRISM Registry: Pseudobulbar Affect Registry Series
NCT01366027
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
NCT00573443
Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy
NCT00113620
Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
NCT00056524
Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
NCT00050232
Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
NCT00021697
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 1 |
| Phase 2 | 5 |
| Phase 3 | 6 |
| Phase 4 | 2 |
Therapeutic Areas
How the Avanir Pharmaceuticals archive is shaped
15 indexed studies, none listed as recruiting (0% open); 14 completed (93%).
Phase mix: 8 late (III/IV) vs 6 early (I/II) (balanced across stages).
Top condition: Depressive Disorder, Treatment-Resistant (1 trial), 4 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Avanir Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 15 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Avanir Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 15 archived trials
- Allakos · 15 trials · 0% recruiting
- Arbor Research Collaborative for Health · 15 trials · 33% recruiting
- Arena Pharmaceuticals · 15 trials · 0% recruiting
- Arrowhead Pharmaceuticals · 15 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Avanir Pharmaceuticals page
15 registered trials is a research-attention snapshot, not an endorsement of Avanir Pharmaceuticals or any single study.
- None of Avanir Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Depressive Disorder, Treatment-Resistant is the condition Avanir Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depressive Disorder, Treatment-Resistant trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Avanir Pharmaceuticals pipeline card: 15 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.